Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • Contact Us
Pipeline News and Updates
Picture

Update for January 31, 2023

1/31/2023

 
Regulatory Update
 
The FDA approved elacestrant (Orserdu, Stemline Therapeutics), on 1/27/2023, for the treatment of estrogen receptor–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
 
The FDA approved pirtobrutinib (Jaypirca, Lilly), on 1/27/2023, for the treatment of relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. 
 
The FDA’s Antimicrobial Drugs Advisory Committee voted 14 to 1 to recommend approval of rezafungin for the treatment of candidemia and invasive candidiasis.
 
The FDA accepted the NDA for gepirone or the treatment of major depressive disorder and set a PDUFA date of 6/23/2023.
 
The FDA granted Moderna’s mRNA vaccine, mRNA-1345, a Breakthrough Therapy Designation for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years or older.
 
The EMA validated the MAA for exagamglogene autotemcel, initiating a full review by CHMP.
 
CHMP recommended that palovarotene to treat fibrodysplasia ossificans progressiva not be approved by the EMA.
 
Announced Research Updates
 
Deciphera announced that in a 453 patient, open-label, Phase III, INTRIGUE trial, treatment with ripretinib did not improve PFS compared to sunitinib in patients with GIST previously treated with imatinib.
 
Peregrine announced that in a 28 patient, Phase II trial, treatment with bavituximab plus pembrolizumab resulted in an ORR of 32.1% in patients with previously untreated advanced hepatocellular carcinoma.
 
Published Research Updates
 
In the 52-week, 159 patient, Phase III, XTEND-1 trial, once weekly treatment with efanesoctocog alfa resulted in an annualized bleeding rate of 0.71 in 133 patients with severe hemophilia A. 26 patents in XTEND-1 received on-demand efanesoctocog alfa and 97% of bleeding episodes resolved after one injection of efanesoctocog alfa.
 
In the 12-week, 140 patient, Phase IIb, ADVISE trial, treatment with etrasimod did not improve the Eczema Area and Severity Index (EASI) compared to placebo in patients with moderate-to-severe atopic dermatitis. 
 
In the 24-week, 195 patient, Phase III, MOMENTUM trial, 25% of patients treated with momelotinib achieved a reduction of at least 50% in their Myelofibrosis Symptom Assessment Form (MFSAF) TSS compared to 9% with danazol in patients with myelofibrosis who were symptomatic and anemic and had been previously treated with an FDA-approved JAK inhibitor.

Three Drugs Added to Knowledgebase

1/26/2023

 
We recently added 3 new drugs to the knowledgebase:
 
  • Dazodalibep a CD40 ligand antagonist for the treatment of Sjögren’s syndrome and rheumatoid arthritis is being developed by Horizon Therapeutics
  • RRx-001 an NLRP3 inhibitor for the treatment oral mucositis in patients receiving radiation and chemotherapy for head and neck cancer is being developed by EpicentRx
  • Bexagliflozin an SGLT-2 for the treatment of type 2 diabetes is being developed by TheracosBio
 
The Prescribe Right Pharmaceutical Pipeline Tracker now allows you to track 1,113 pipeline and recently approved drugs supported by 2,952 announced and published study results.

Update for January 25, 2023

1/25/2023

 
Regulatory Update
 
The FDA approved bexagliflozin (Brenzavvy, TheracosBio), on 1/20/2023, to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
 
The FDA granted granted tecarfarin a Fast Track designation for the prevention of systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation. 
 
Finch discontinued the Phase III PRISM4 trial in January 2023, while the company examines the value of its intellectual property estate and other assets. The PRISM4 trial was evaluating CP101 in the prevention of recurrent C. difficile infection.

Update for January 18, 2023

1/18/2023

 
Regulatory Update

Medexus and Medac estimate it will take up to a year to collect and submit all data requested by the FDA for the resubmitted NDA for treosulfan.

Announced Research Updates

Oramed announced that in the 26-week, 710 patient, Phase III, ORA-D-013-1 trial, oral insulin did not improve HbA1c or fasting plasma glucose compared to placebo in patients with type 2 diabetes that was not controlled by at least one antihyperglycemic agent.

Published Research Updates

In the 12-week, 153-patient, Phase IIb, D1AMOND trial, treatment with ecopipam reduced the YGTSS-TTS by 3.44 points compared to placebo in patients aged 6 to 17 years with Tourette syndrome.
​
Subscribers received a total of EIGHT study results this week. Contact us today for a subscription.

25 Drugs Added to Knowledgebase

1/13/2023

 
We recently added 25 new drugs to the knowledgebase:
 
  • Domvanalimab a monoclonal antibody for TIGIT for the treatment of non-small cell lung cancer (NSCLC), unresectable or metastatic gastric, esophageal and gastro-esophageal junction adenocarcinomas is being developed by Arcus Biosciences
  • RGI-2001 an alpha-galactosylceramide analog for prophylaxis of acute graft-versus-host disease (aGVHD) is being developed by REGiMMUNE
  • mRNA-4157/V940 a cancer vaccine for the treatment of Stage III/IV melanoma following complete resection is being developed by Moderna and Merck
  • Glofitamab a bispecific antibody for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is being developed by Roche
  • Elranatamab a bispecific antibody for the treatment of relapsed or refractory multiple myeloma is being developed by Pfizer
  • Odronextamab a bispecific antibody for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is being developed by Regeneron Pharmaceuticals
  • PRA023 an anti-TL1A monoclonal antibody for the treatment of ulcerative colitis, Crohn’s disease and sclerosis-associated interstitial lung disease is being developed by Prometheus Biosciences
  • NCX 470 a nitric oxide (NO)-donating prostaglandin analogue for the treatment of open-angle glaucoma or ocular hypertension is being developed by Nicox
  • TAK-279 a TYK2 inhibitor for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis is being developed by Takeda, Nimbus Therapeutics
  • Talquetamab a bispecific antibody for the treatment of relapsed or refractory multiple myeloma is being developed by Johnson & Johnson
  • Lyme disease vaccine - Valneva a vaccine for the prevention of Lyme disease is being developed by Pfizer and Valneva
  • Stannous protoporphyrin, iron sucrose a heme oxygenase inhibitor to reduce the risk of postoperative complications following cardiothoracic surgery is being developed by Renibus Therapeutics
  • Ganaplacide an imidazolopiperazine for the treatment of malaria is being developed by Novartis
  • ARV-471 a proteolysis targeting chimeric (PROTAC) for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. is being developed by Arvinas
  • Glutamic acid decarboxylase-65 (GAD65) a glutamic acid decarboxylase for the preservation of endogenous insulin production is being developed by Diamyd Medical
  • IONIS-FB-LRx an antisense drug for the treatment of immunoglobulin A nephropathy (IgAN) and Age-Related Macular Degeneration (AMD) is being developed by Roche and Ionis Pharmaceuticals
  • Denileukin diftitox a fusion protein for the treatment of persistent or recurrent cutaneous T-cell lymphoma is being developed by Citius Pharmaceuticals
  • Lutetium-177-edotreotide an octreotide-derived somatostatin analog attached to a low-energy beta-emitting therapeutic radioisotope for the treatment of gastroenteropancreatic neuroendocrine tumors is being developed by ITM Isotope Technologies Munich SE
  • Acoziborole a benzoxaborole for the treatment of Human African trypanosomiasis caused by Trypanosoma brucei gambiense is being developed by Sanofi
  • Baxdrostat an aldosterone synthase inhibitor for the treatment of treatment-resistant hypertension and primary aldosteronism is being developed by CinCor Pharma
  • Zolbetuximab an anti-CLDN18.2 monoclonal antibody for the treatment of Claudin 18.2 (CLDN18.2)-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma is being developed by Astellas Pharma
  • Ecopipam a dopamine D1 receptor antagonist for the treatment of Tourette syndrome is being developed by Emalex Biosciences and Psyadon Pharmaceuticals
  • Anacaulase a proteolytic enzyme for the removal of eschar in adults with deep partial-thickness and/or full-thickness thermal burns is being developed by MediWound
  • RVT-3101 a Tumor necrosis factor α-like ligand 1A (TL1A) antibody for the treatment of ulcerative colitis and Crohn’s Disease is being developed by Roivant Sciences
  • TAK-755 an ADAMTS13 replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP) is being developed by Takeda
 
The Prescribe Right Pharmaceutical Pipeline Tracker now allows you to track 1,111 pipeline and recently approved drugs supported by 2,934 announced and published study results

Update for January 12, 2023

1/12/2023

 
Regulatory Update
 
The FDA approved lecanemab (Leqembi, Eisai & Biogen), on 1/6/2023, too slow the reduction in cognition in Alzheimer’s patients with mild cognitive impairment or mild dementia. Eisai & Biogen set WAC for at lecanemab $26,500 per year.
 
The FDA accepted the BLA for nirsevimab for the prevention of respiratory syncytial virus (RSV) in newborns and infants with an approval decision anticipated in 3Q23.
 
The FDA accepted the BLA for rozanolixizumab for the treatment of generalized myasthenia gravis in patients who are anti-acetycholine receptor or anti-muscle-specific tyrosine kinase antibody positive with an approval decision expected by the end of 2Q23
 
The FDA accepted the BLA for glofitamab for the treatment of relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy and set a PDUFA date for 7/1/2023.
 
The FDA accepted the NDA for vamorolone for the treatment of Duchenne muscular dystrophy (DMD) and set a PDUFA date for 10/26/2023.
 
The FDA has placed a hold on the launch of vonoprazan until acceptable levels of nitrosamine and met and maintained throughout the shelf-life of the product.
 
Checkpoint Therapeutics submitted a BLA for cosibelimab for the treatment of metastatic cutaneous squamous cell carcinoma.
 
Novan submitted an NDA for berdazimer gel for the treatment of molluscum contagiosum.
 
The FDA granted an Orphan Drug Designation to azeliragon for the treatment of glioblastoma.

Update for January 6, 2023

1/6/2023

 
Regulatory Update
 
The FDA approved lenacapavir (Sunlenca, Gilead Sciences), on 12/22/2022, for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection. Lenacapavir is initiated as a combination of oral tablets with the first subcutaneous injection. After the loading dose, a subcutaneous injection of lenacapavir is given every six months. According to Endpoints News WAC for the first year of lenacapavir will be $42,250 with subsequent years costing $39,000.
 
The FDA approved mosunetuzumab (Lunsumio, Genentech, Roche), on 12/22/2022, for the treatment of relapsed or refractory follicular lymphoma in patients who have received at least two previous systemic therapies.
 
The FDA approved ublituximab (Briumvi, TG Therapeutics), on 12/28/2022, for the treatment of relapsing forms of multiple sclerosis in adults.
 
The FDA delayed a decision on toripalimab, until a site inspection of the manufacturing facility can be completed. Due to COVID-19 related restrictions on travel in China, an inspection had not been competed in December 2022.
 
The FDA rejected palovarotene and requested additional details on clinical trials in December 2022.
 
The FDA accepted the resubmitted BLA for bimekizumab for the treatment of moderate to severe plaque psoriasis with approval expected in 2Q23.
 
The FDA has placed a hold on the Phase III VITESSE trial, evaluating Viaskin Peanut, until DBV makes changes to the study protocol regarding statistical analysis and total number of patients. DBV modified the VITESSE protocol, and the FDA lifted the hold in December 2022.
 
SpringWorks submitted an NDA for nirogacestat for the treatment of adults with desmoid tumors.
 
Published Research Updates
 
In a review of fezolinetant, ICER found evidence to support a health benefit for fezolinetant in the treatment of vasomotor symptoms to be insufficient compared to menopausal hormone therapy. Longer-term safety and efficacy data are needed to determine the place in therapy for fezolinetant. ICER estimated a Health Benefit Price Benchmark for fezolinetant to be $2,000 to $2,500 per year.
 
ICER found evidence to support use of lecanemab to slow the development of mild cognitive impairment in early Alzheimer's disease to be promising but inconclusive with the possibility for harm due to ARIA. ICER estimated a range to meet cost-effectiveness criteria to be $8,500 to $20,600 per year. 
 
ICER found evidence to support use of donanemab to slow the development of mild cognitive impairment in early Alzheimer's disease to be insufficient, with only data from a Phase II trial available. There is also the with the possibility for harm due to ARIA. ICER assumed the drug would be as effective as lecanemab to estimate a range to meet cost-effectiveness criteria to be $14,500 and $46,900 per year. 
 
An ICER review concluded there was a moderate certainty of a comparable, small, or substantial health benefit with etranacogene dezaparvovec compared to factor IX therapy for the treatment of severe hemophilia B. While etranacogene dezaparvovec offers a clinical benefit, ICER was concerned about the duration of the benefit with long-term data only available through 18 months for 54 patients. There was also concern about potential long-term harms to liver function and hepatocellular carcinoma. ICER estimated a Health Benefit Price Benchmark (HBPB) of $2.93 million to $2.96 million for a single dose of etranacogene dezaparvovec.
 
An ICER review concluded there was a moderate certainty of a comparable, small, or substantial health benefit with valoctocogene roxaparvovec compared to factor VIII prophylaxis for the treatment of severe hemophilia A without inhibitors. When comparing valoctocogene roxaparvovec to emicizumab, ICER found limitations due to the small amount of data available to compare the drugs. They concluded there was low certainty for a net health benefit with valoctocogene roxaparvovec compared to emicizumab. While valoctocogene roxaparvovec offers a clinical benefit, ICER was concerned about the duration of the benefit and potential long-term harms to liver function and hepatocellular carcinoma. ICER estimated a Health Benefit Price Benchmark (HBPB) of $1.96 million for a single dose of valoctocogene roxaparvovec.

    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    May 2023
    April 2023
    March 2023
    February 2023
    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.